Atherotech, Inc. (Atherotech), a cardio-diagnostic company focusing on cardiometabolic tests, has appointed Michael Cobble as its chief medical officer (CMO). As CMO, Cobble responsibilities will include educating the public and health care professionals about Atherotech's line of cardiometabolic tests. He will also be responsible for furthering understanding and acceptance of the VAP(R) (Vertical Auto Profile) Cholesterol Test in advanced lipid testing.
Cobble is director of Canyons Medical Center in Sandy, Utah. Cobble is a primary care physician, board-certified lipidologist and certified hypertension specialist.
Cobble succeeds James Ehrlich, M.D., who will continue to serve as a medical consultant to Atherotech while pursuing advocacy efforts for the early detection and prevention of heart disease.
Cobble will maintain his role at Canyons Medical Center and continue to practice a full range of medicine, including diabetes care, cardiovascular disease, hypertension, dyslipidemia, and bipolar and mood disorders.
Cobble is a member of the American Academy of Family Practice and a board member as well as secretary for the Pacific Lipid Association. He is a member of the National Lipid Association, a board-certified clinical lipidologist and fellow of the National Lipid Association. He is also a member of the American Society of Hypertension and is recognized as a clinical hypertension specialist.
Since completing medical school and residency in the early ’90s, he has obtained a master’s degree in psychopharmacology, and his practice is a referral clinic for the Harvard Bipolar Research Group. He lectures extensively and has published articles on topics ranging from pathophysiology and lipidology to the treatment of diabetes.